Aldeyra Therapeutics IncNASDAQ:ALDX
- LAST PRICE5.3900
- TODAY'S CHANGE (%)-0.1100 (-2.0000%)
- Bid / Lots5.2700/ 5
- Ask / Lots5.6000/ 10
- Open / Previous Close5.4500 / 5.5000
- Day Range
- 52 Week Range
- Volume1,204,850
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ALDX |
|---|---|---|
| 09:32 ET | 5083 | 5.45 |
| 09:34 ET | 17394 | 5.49 |
| 09:36 ET | 1576 | 5.455 |
| 09:38 ET | 11391 | 5.365 |
| 09:39 ET | 20397 | 5.435 |
| 09:41 ET | 1606 | 5.47 |
| 09:43 ET | 3000 | 5.485 |
| 09:45 ET | 8108 | 5.54 |
| 09:48 ET | 3800 | 5.51 |
| 09:50 ET | 10246 | 5.54 |
| 09:52 ET | 1600 | 5.52 |
| 09:54 ET | 1454 | 5.545 |
| 09:56 ET | 1000 | 5.57 |
| 09:57 ET | 3520 | 5.54 |
| 09:59 ET | 4500 | 5.59 |
| 10:01 ET | 1159 | 5.6 |
| 10:03 ET | 700 | 5.6 |
| 10:06 ET | 1440 | 5.6 |
| 10:08 ET | 4489 | 5.58 |
| 10:10 ET | 657 | 5.569 |
| 10:12 ET | 1206 | 5.575 |
| 10:14 ET | 31855 | 5.56 |
| 10:15 ET | 1415 | 5.59 |
| 10:17 ET | 1926 | 5.55 |
| 10:21 ET | 3088 | 5.53 |
| 10:24 ET | 389 | 5.525 |
| 10:26 ET | 5860 | 5.5416 |
| 10:28 ET | 955 | 5.54 |
| 10:30 ET | 500 | 5.5319 |
| 10:32 ET | 426 | 5.57 |
| 10:33 ET | 300 | 5.58 |
| 10:35 ET | 200 | 5.59 |
| 10:37 ET | 731 | 5.595 |
| 10:39 ET | 428 | 5.59 |
| 10:42 ET | 100 | 5.58 |
| 10:44 ET | 100 | 5.6 |
| 10:46 ET | 900 | 5.56 |
| 10:48 ET | 100 | 5.57 |
| 10:50 ET | 835 | 5.53 |
| 10:53 ET | 486 | 5.52 |
| 10:55 ET | 1200 | 5.495 |
| 10:57 ET | 15925 | 5.4905 |
| 11:00 ET | 300 | 5.52 |
| 11:02 ET | 1840 | 5.46 |
| 11:06 ET | 100 | 5.48 |
| 11:08 ET | 1857 | 5.495 |
| 11:09 ET | 2990 | 5.49 |
| 11:11 ET | 1014 | 5.48 |
| 11:13 ET | 622 | 5.49 |
| 11:15 ET | 200 | 5.51 |
| 11:18 ET | 2863 | 5.48 |
| 11:20 ET | 100 | 5.49 |
| 11:22 ET | 500 | 5.51 |
| 11:24 ET | 500 | 5.49 |
| 11:26 ET | 100 | 5.51 |
| 11:27 ET | 500 | 5.48 |
| 11:29 ET | 100 | 5.49 |
| 11:31 ET | 300 | 5.47 |
| 11:33 ET | 2565 | 5.49 |
| 11:36 ET | 200 | 5.49 |
| 11:38 ET | 300 | 5.49 |
| 11:40 ET | 1644 | 5.47 |
| 11:42 ET | 3548 | 5.46 |
| 11:45 ET | 300 | 5.46 |
| 11:47 ET | 300 | 5.45 |
| 11:49 ET | 1200 | 5.43 |
| 11:54 ET | 408 | 5.43 |
| 11:56 ET | 696 | 5.43 |
| 11:58 ET | 100 | 5.43 |
| 12:02 ET | 600 | 5.425 |
| 12:03 ET | 1177 | 5.41 |
| 12:05 ET | 2000 | 5.39 |
| 12:07 ET | 1127 | 5.39 |
| 12:12 ET | 919 | 5.4 |
| 12:14 ET | 526 | 5.39 |
| 12:16 ET | 400 | 5.4 |
| 12:18 ET | 400 | 5.4 |
| 12:20 ET | 1400 | 5.41 |
| 12:21 ET | 100 | 5.42 |
| 12:23 ET | 300 | 5.42 |
| 12:25 ET | 500 | 5.43 |
| 12:27 ET | 1600 | 5.43 |
| 12:30 ET | 200 | 5.44 |
| 12:32 ET | 300 | 5.43 |
| 12:34 ET | 200 | 5.44 |
| 12:36 ET | 400 | 5.44 |
| 12:38 ET | 500 | 5.44 |
| 12:39 ET | 1800 | 5.44 |
| 12:41 ET | 800 | 5.43 |
| 12:43 ET | 632 | 5.44 |
| 12:45 ET | 2628 | 5.3952 |
| 12:48 ET | 100 | 5.42 |
| 12:50 ET | 100 | 5.41 |
| 12:52 ET | 1000 | 5.408 |
| 12:54 ET | 100 | 5.41 |
| 12:56 ET | 200 | 5.42 |
| 12:57 ET | 1700 | 5.41 |
| 01:01 ET | 1858 | 5.38 |
| 01:03 ET | 3419 | 5.35 |
| 01:08 ET | 874 | 5.37 |
| 01:10 ET | 218 | 5.37 |
| 01:12 ET | 11171 | 5.42 |
| 01:14 ET | 803 | 5.41 |
| 01:15 ET | 200 | 5.41 |
| 01:17 ET | 102 | 5.3966 |
| 01:19 ET | 1050 | 5.41 |
| 01:21 ET | 200 | 5.41 |
| 01:24 ET | 600 | 5.41 |
| 01:26 ET | 4712 | 5.38 |
| 01:28 ET | 200 | 5.38 |
| 01:32 ET | 7693 | 5.33 |
| 01:33 ET | 200 | 5.33 |
| 01:37 ET | 1414 | 5.32 |
| 01:39 ET | 1913 | 5.32 |
| 01:42 ET | 600 | 5.32 |
| 01:44 ET | 4063 | 5.3 |
| 01:46 ET | 11941 | 5.31 |
| 01:48 ET | 326 | 5.32 |
| 01:50 ET | 400 | 5.32 |
| 01:51 ET | 300 | 5.32 |
| 01:53 ET | 318 | 5.3299 |
| 01:55 ET | 889 | 5.33 |
| 01:57 ET | 1821 | 5.34 |
| 02:00 ET | 1714 | 5.33 |
| 02:04 ET | 100 | 5.33 |
| 02:06 ET | 200 | 5.34 |
| 02:08 ET | 1300 | 5.32 |
| 02:09 ET | 126 | 5.31 |
| 02:11 ET | 200 | 5.31 |
| 02:13 ET | 1767 | 5.29 |
| 02:15 ET | 7646 | 5.27 |
| 02:18 ET | 1700 | 5.26 |
| 02:20 ET | 917 | 5.28 |
| 02:22 ET | 1704 | 5.27 |
| 02:24 ET | 7363 | 5.29 |
| 02:26 ET | 1259 | 5.3 |
| 02:27 ET | 3140 | 5.32 |
| 02:29 ET | 361 | 5.33 |
| 02:31 ET | 300 | 5.34 |
| 02:33 ET | 1050 | 5.34 |
| 02:36 ET | 100 | 5.34 |
| 02:38 ET | 1967 | 5.35 |
| 02:40 ET | 100 | 5.34 |
| 02:42 ET | 689 | 5.35 |
| 02:44 ET | 200 | 5.35 |
| 02:45 ET | 300 | 5.36 |
| 02:47 ET | 300 | 5.36 |
| 02:49 ET | 1127 | 5.37 |
| 02:51 ET | 1785 | 5.3542 |
| 02:54 ET | 100 | 5.36 |
| 02:56 ET | 100 | 5.36 |
| 02:58 ET | 700 | 5.34 |
| 03:00 ET | 600 | 5.33 |
| 03:02 ET | 1079 | 5.32 |
| 03:03 ET | 840 | 5.3201 |
| 03:09 ET | 5888 | 5.31 |
| 03:12 ET | 400 | 5.33 |
| 03:14 ET | 1230 | 5.3 |
| 03:16 ET | 500 | 5.32 |
| 03:18 ET | 300 | 5.32 |
| 03:20 ET | 1194 | 5.32 |
| 03:21 ET | 500 | 5.33 |
| 03:23 ET | 200 | 5.34 |
| 03:25 ET | 4928 | 5.35 |
| 03:27 ET | 601 | 5.37 |
| 03:30 ET | 2800 | 5.38 |
| 03:32 ET | 600 | 5.38 |
| 03:34 ET | 1631 | 5.37 |
| 03:36 ET | 1617 | 5.36 |
| 03:38 ET | 100 | 5.37 |
| 03:39 ET | 700 | 5.365 |
| 03:41 ET | 1400 | 5.37 |
| 03:43 ET | 1674 | 5.36 |
| 03:45 ET | 1950 | 5.365 |
| 03:48 ET | 2207 | 5.36 |
| 03:50 ET | 4203 | 5.35 |
| 03:52 ET | 4985 | 5.38 |
| 03:54 ET | 6727 | 5.37 |
| 03:56 ET | 8887 | 5.379 |
| 03:57 ET | 4782 | 5.375 |
| 03:59 ET | 708957 | 5.39 |
Sep 5, 2024
Aldeyra Therapeutics to Participate in the H.C. Wainwright 26(th) Annual Global Investment Conference, from 7:00AM ET on Thursday Sep 05, 2024 by Dow Jones
7:00AM ET on Thursday Sep 05, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Aldeyra Therapeutics Inc | 358.3M | -8.4x | --- |
Nautilus Biotechnology Inc | 363.7M | -5.2x | --- |
Black Diamond Therapeutics Inc | 349.8M | -2.8x | --- |
Monte Rosa Therapeutics Inc | 372.9M | -2.4x | --- |
Jasper Therapeutics Inc | 343.6M | -3.7x | --- |
Alto Neuroscience Inc | 374.0M | --- | --- |
Company Information
Aldeyra Therapeutics, Inc. is a biotechnology company, which is engaged in discovering therapies designed to treat immune-mediated diseases. The Company's product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX-246, ADX-248, and chemically related molecules for the treatment of systemic and retinal immune-mediated diseases. Its pre-commercial product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the treatment of proliferative vitreoretinopathy and retinitis pigmentosa. Its ADX-629, is an orally administered RASP modulator in clinical development for atopic dermatitis, idiopathic nephrotic syndrome, moderate alcohol-associated hepatitis, chronic cough, and Sjogren-Larsson Syndrome. Its preclinical RASP platform includes ADX-246 and ADX-248 in development for metabolic, retinal diseases and systemic inflammatory diseases.
Contact Information
- Headquarters
- 131 HARTWELL AVENUE, SUITE 320LEXINGTON, MA, United States 02421
- Phone
- 781-761-4904
- Fax
- 302-636-5454
Executives
- Independent Chairman of the Board
- Richard Douglas
- President, Chief Executive Officer, Director
- Todd Brady
- Principal Financial Officer and Principal Accounting Officer
- Michael Alfieri
- Chief Development Officer
- Stephen Machatha
- Independent Director
- Ben Bronstein
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $358.3M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 59.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.43 |
EPS | $-0.64 |
Book Value | $2.02 |
P/E Ratio | -8.4x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
